Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott F Huntington

Showing results (61-70 of 81) with videos related to

Pageof 9
Sort By:
Leukemia & Lymphoma|April 22, 2024
Cost-effectiveness of adding quizartinib to induction chemotherapy for patients with <i>FLT3-</i>mutant acute myeloid leukemiaJan Philipp Bewersdorf, Kishan K Patel, Rory M Shallis, et al.
Cancer Medicine|September 13, 2023
Statin use, survival and incidence of thrombosis among older patients with polycythemia vera and essential thrombocythemiaNikolai A Podoltsev, Rong Wang, Rory M Shallis, et al.
Pharmacology Research & Perspectives|November 2, 2024
Identification of cytokine release syndrome and indicators of severity in retrospective databases among patients receiving immunotherapyScott F Huntington, Dee Lin, Marie-Hélène Lafeuille, et al.
Leukemia & Lymphoma|May 2, 2024
Real-world patterns and sequences of targeted therapy use in chronic lymphocytic leukemia and small lymphocytic lymphoma in the United States: a longitudinal studyScott F Huntington, Wendy Y Cheng, Eric M Sarpong, et al.
Blood Advances|April 21, 2020
Patterns of care and clinical outcomes with cytarabine-anthracycline induction chemotherapy for AML patients in the United StatesAmer M Zeidan, Nikolai A Podoltsev, Xiaoyi Wang, et al.
Blood Advances|July 28, 2025
Cost-Effectiveness of Upfront vs. Delayed Allogeneic Hematopoietic Stem Cell Transplant for Intermediate Risk AMLAbdulrahman Alhajahjeh, Kishan Patel, Nikolai A Podoltsev, et al.
JAMA Network Open|June 5, 2023
The COVID-19 Pandemic and In-Person Visit Rate Disruptions Among Patients With Hematologic Neoplasms in the US in 2020 to 2021Gaurav Goyal, Krystal W Lau, Xiaoliang Wang, et al.
British Journal of Haematology|September 22, 2016
Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromesAmer M Zeidan, Amy J Davidoff, Jessica B Long, et al.
Leukemia & Lymphoma|July 12, 2026
Treatment inequity among older adults with newly diagnosed acute myeloid leukemia ineligible for intensive therapyAlain Mina, Yanqing Xu, Tatyana A Kapustyan, et al.
Plos One|September 14, 2017
Risk of myeloid neoplasms after radiotherapy among older women with localized breast cancer: A population-based studyAmer M Zeidan, Jessica B Long, Rong Wang, et al.
Pageof 9

Showing results (61-70 of 81) with videos related to

Sort By:
Pageof 9
Leukemia & Lymphoma|April 22, 2024
Cost-effectiveness of adding quizartinib to induction chemotherapy for patients with <i>FLT3-</i>mutant acute myeloid leukemiaJan Philipp Bewersdorf, Kishan K Patel, Rory M Shallis, et al.
Cancer Medicine|September 13, 2023
Statin use, survival and incidence of thrombosis among older patients with polycythemia vera and essential thrombocythemiaNikolai A Podoltsev, Rong Wang, Rory M Shallis, et al.
Pharmacology Research & Perspectives|November 2, 2024
Identification of cytokine release syndrome and indicators of severity in retrospective databases among patients receiving immunotherapyScott F Huntington, Dee Lin, Marie-Hélène Lafeuille, et al.
Leukemia & Lymphoma|May 2, 2024
Real-world patterns and sequences of targeted therapy use in chronic lymphocytic leukemia and small lymphocytic lymphoma in the United States: a longitudinal studyScott F Huntington, Wendy Y Cheng, Eric M Sarpong, et al.
Blood Advances|April 21, 2020
Patterns of care and clinical outcomes with cytarabine-anthracycline induction chemotherapy for AML patients in the United StatesAmer M Zeidan, Nikolai A Podoltsev, Xiaoyi Wang, et al.
Blood Advances|July 28, 2025
Cost-Effectiveness of Upfront vs. Delayed Allogeneic Hematopoietic Stem Cell Transplant for Intermediate Risk AMLAbdulrahman Alhajahjeh, Kishan Patel, Nikolai A Podoltsev, et al.
JAMA Network Open|June 5, 2023
The COVID-19 Pandemic and In-Person Visit Rate Disruptions Among Patients With Hematologic Neoplasms in the US in 2020 to 2021Gaurav Goyal, Krystal W Lau, Xiaoliang Wang, et al.
British Journal of Haematology|September 22, 2016
Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromesAmer M Zeidan, Amy J Davidoff, Jessica B Long, et al.
Leukemia & Lymphoma|July 12, 2026
Treatment inequity among older adults with newly diagnosed acute myeloid leukemia ineligible for intensive therapyAlain Mina, Yanqing Xu, Tatyana A Kapustyan, et al.
Plos One|September 14, 2017
Risk of myeloid neoplasms after radiotherapy among older women with localized breast cancer: A population-based studyAmer M Zeidan, Jessica B Long, Rong Wang, et al.
Pageof 9